资讯

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late ...

Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, ...
Medscape

Ruxolitinib Cream Approved for Children Aged 2-11 With Atopic Dermatitis

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of ...